![Neeraj Agarwal, MD, FASCO on Twitter: "Mitomycin gel receives FDA approval today as the 1st drug therapy for low grade upper tract urothelial carcinoma: Based on 58% CR noted in the OLYMPUS Neeraj Agarwal, MD, FASCO on Twitter: "Mitomycin gel receives FDA approval today as the 1st drug therapy for low grade upper tract urothelial carcinoma: Based on 58% CR noted in the OLYMPUS](https://pbs.twimg.com/media/EVrFmtQUEAA9d5c.jpg:large)
Neeraj Agarwal, MD, FASCO on Twitter: "Mitomycin gel receives FDA approval today as the 1st drug therapy for low grade upper tract urothelial carcinoma: Based on 58% CR noted in the OLYMPUS
Weill Cornell Genitourinary Cancer Program - One-minute rundown: In this OncLive video, Dr. Scott Tagawa discusses the benefits of radium-223 dichloride (Xofigo) in prostate cancer. https://bit.ly/3BB1W98 | Facebook
![St. Jude Research on Twitter: "Dr. Thomas E. Merchant discusses the incidence of the brain tumor craniopharyngioma. Watch on @OncLive. https://t.co/2mr8ritRMg #RareDiseaseDay https://t.co/v8E5c8C4Jj" / Twitter St. Jude Research on Twitter: "Dr. Thomas E. Merchant discusses the incidence of the brain tumor craniopharyngioma. Watch on @OncLive. https://t.co/2mr8ritRMg #RareDiseaseDay https://t.co/v8E5c8C4Jj" / Twitter](https://pbs.twimg.com/media/EvVrWr8XMAE4mH9.jpg)
St. Jude Research on Twitter: "Dr. Thomas E. Merchant discusses the incidence of the brain tumor craniopharyngioma. Watch on @OncLive. https://t.co/2mr8ritRMg #RareDiseaseDay https://t.co/v8E5c8C4Jj" / Twitter
![University of Illinois Cancer Center Strategic Alliance Partnership: OncLive - University of Illinois Cancer Center University of Illinois Cancer Center Strategic Alliance Partnership: OncLive - University of Illinois Cancer Center](https://cancer.uillinois.edu/wp-content/uploads/2021/12/Jain-Onclive1-360x215.png)